News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Entrectinib Achieves High Response Rate Across Solid Tumors

Al's Comment:

 This is an experimental treatment of a new targeted drug which hits 3 targets: NTRK, ROS-1 and ALK.  Might be worth trying this trial (or trying to get it on compassionate use if you do not fit the trial) if your genomic report mentions you have 2 or 3 of these targets overexpressed.

Go to for the current trials with this drug.

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source:

(Everything below this line is from!)

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557